the impact of selpercatinib in patients with ret fusion-positive nsclc
Published 2 years ago • 724 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
2:52
updated overall efficacy and safety of selpercatinib in patients with ret fusion nsclc
-
7:34
intracranial activity of selpercatinib in ret fusion positive nsclc
-
1:48
selpercatinib induced durable efficacy in ret fusion-positive nsclc
-
2:48
ret fusion-positive mnsclc: selpercatinib and pralsetinib
-
7:02
fda approval of selpercatinib for ret fusion positive nsclc and thyroid cancers
-
3:58
highlights on selpercatinib in ret fusion-positive nsclc: the libretto-431 study
-
2:21
pralsetinib in chinese patients with advanced ret fusion nsclc
-
0:39
phase i/ii study of adapt-001 plus an ici for patients with immune refractory cancers
-
6:42
selpercatinib benefit, with or without pembro, in first-line advanced ret fusion-positive nsclc
-
9:54
efficacy and safety of selpercatinib in ret fusion-positive cancers other than lung or thyroid c...
-
2:58
[lung] effect of selpercatinib for ret-positive patients
-
1:45
targeting ret in lung cancer
-
3:49
ret fusion treatment: selpercatinib - targeted therapies in lung cancer 2023
-
6:04
arrow: clinical activity of pralsetinib in ret-fusion positive solid tumors
-
7:20
arrow points the way for ret fusion-positive nsclc treatment | stephen liu
-
1:13
selpercatinib data underscore value of precision medicine in ret-driven lung cancer
-
1:02:07
selpercatinib in ret-altered thyroid cancers with dr. lori wirth
-
12:19
arrow study: pralsetinib in ret fusion tumors
-
3:18
arrow update confirms pralsetinib benefit for ret fusion-positive advanced nsclc | stephen liu